Therefore, our findings warrant further investigations to reveal the synergistic effects of the statin class of medications with tyrosine kinase inhibitors against ErbB2 in the clinical management of ErbB2-positive breast cancers. This evidence concerns the gene ERBB2 and breast cancer.